Viewing Study NCT03711032


Ignite Creation Date: 2025-12-24 @ 9:24 PM
Ignite Modification Date: 2025-12-31 @ 7:47 AM
Study NCT ID: NCT03711032
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-22
First Post: 2018-10-15
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module